Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 6Thoracic 1Other solid neoplasm 1Head & Neck 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Colorectal Neoplasms 29Carcinoma, Non-Small-Cell Lung 17Pancreatic Neoplasms 12Neoplasm Metastasis 9Stomach Neoplasms 7Lung Neoplasms 7Rectal Neoplasms 6Neoplasms 6Melanoma 6Esophageal Neoplasms 6Colonic Neoplasms 6Ovarian Neoplasms 4Gastrointestinal Neoplasms 4Breast Neoplasms 4Prostatic Neoplasms 3Head and Neck Neoplasms 3Carcinoma, Renal Cell 3Triple Negative Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Neoplasms by Site 2Liver Neoplasms 2Hypopharyngeal Neoplasms 2Endometrial Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Pancreatic Ductal 2Biliary Tract Neoplasms 2Sarcoma 1Salivary Gland Neoplasms 1Recurrence 1Rectal Diseases 1

Interventions

pembrolizumab 13Gemcitabine 12Cyclophosphamide 10Carboplatin 10Specimen Handling 8Magnetic Resonance Spectroscopy 8Cisplatin 8Docetaxel 7X-Rays 6Filgrastim 6Doxorubicin 6Biopsy 6tislelizumab 5Radiosurgery 5Phantoms, Imaging 5Paclitaxel 5Nivolumab 5Irinotecan 5Bevacizumab 5130-nm albumin-bound paclitaxel 5spartalizumab 4palbociclib 4Thiotepa 4Temozolomide 4Radiotherapy 4Nuclear Medicine Department, Hospital 4Mesna 4Ipilimumab 4Imatinib Mesylate 4Ifosfamide 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma × Pemetrexed × Gastrointestinal × Clear all
NCT00703638 2017-11-29

Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors

Masonic Cancer Center, University of Minnesota

Phase 1 Completed
16 enrolled
BreastGastrointestinalGenitourinaryHead & NeckOther solid neoplasmSarcomaThoracic

Breast Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Mesothelioma, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡